Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial

Journal of Bone and Mineral Research

Volumn 15, Issue 6, 2000, Pages 1006-1013

  Reid, David M ^a   Hughes, Rodney A ^b   Laan, Roland F J M ^c   Sacco Gibson, Nancy A ^d   Wenderoth, Dietrich H ^e   Adami, Silvano ^f   Eusebio, Rachelle A ^d   Devogelaer, Jean Pierre ^g  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ST PETER S HOSPITAL   (United Kingdom)

^c Academisch Ziekenhuis   (Netherlands)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e PROCTER AND GAMBLE COMPANY   (United States)

^f Centro Osteoporosi   (Italy)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bisphosphonate; Corticosteroids; Osteoporosis; Risedronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

EID: 0034036235     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.6.1006     Document Type: Article

References (29)

1. Reid IR 1997 Glucocorticoid osteoporosis - mechanisms and management. Eur J Endocrinol 137:209-217.
2. Adachi JD 1997 Corticosteroid-induced osteoporosis. Am J Med Sci 313:41-49.
3. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D; DellaRocca C 1990 Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39-51.
4. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA 1993 Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: A randomized, controlled study. Ann Intern Med 119:963-968.
5. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J 1991 Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study. Thorax 46:803-806.
6. Lowik C, van der Pluijm L 1995 Mechanisms of action of bisphosphonates: Studies with bone culture systems. In: Bijvoet HA, Fleisch G, Canfield RE, Russell RGG (eds.) Bisphosphonate on Bones. Elsevier Science, New York, NY, U.S.A., pp. 155-170.
7. Siris ES, Chines AA, Altman RD, Brown JP, Johnston Jr CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study. J Bone Miner Res 13:1032-1038.
8. Singer FR, Clemens TL, Eusebio RA, Bekker PJ 1998 Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83: 1906-1910.
9. Brown JP, Hosking DJ, Ste-Marie L, Johnston CC, Jr., Reginster J, Ryan WG, Johnson TD, Bekker PJ 1999 Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study. Calcif Tissue Int 64:93-99.
10. Mortensen L, Charles P, Bekker PJ, DiGennaro J, Johnston CC Jr 1998 Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396-402.
11. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962.
12. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C 1994 Universal standardization for dual x-ray absorptiometry: Patient and phantom cross-calibration results. J Bone Miner Res 9:1503-1514.
13. Steiger P, Ganant HK, German ME, Hangartner T, Hanson J, Kalender WA, Mazess R, Morita R, Schlessl H, Steiger P, Stein J, Tarnegal T 1995 Standardization of spine BMD measurements. J Bone Miner Res 10:1602-1603.
14. Faulkner KG, McClung MR 1995 Quality control of DXA instruments in multicenter trials. Osteoporos Int 5:218-227.
15. Melton III LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL 1993 Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113-119.
16. Kiel D 1995 Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures [published erratum appears in J Bone Miner Res 1995 Oct: 10(10): 1605.]. J Bone Miner Res 10:518-523.
17. Kiel D 1995 Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures [published erratum appears in J Bone Miner Res 1995 Oct: 10(10): 1605.]. J Bone Miner Res 10:518-523.
18. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH 1996 Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followup. J Rheumatol 23:995-1000.
19. Reid IR, Wattie DJ, Evans MC, Stapleton JP 1996 Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 10:1173-1177.
20. Hall GM, Daniels M, Doyle DV, Spector TD 1994 Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37:1499-1505.
21. Devogelaer JP, Esselinckx W, Nagant de Deuxchaisnes C 1994 Calcidiol protects bone mass in rheumatoid arthritis patients treated by low dose glucocorticoids. In: Norman AW, Bouillon R, Thomasset M (eds.) Ninth Workshop on Vitamin D. Walter de Gruyter, Berlin. pp. 855-856.
22. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J 1993 Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747-1752.
23. Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, Sturtridge WC, Sebaldt RJ, Steele M, Gordon M, Themeles E, Tugwell P, Roberts R, Gent M 1997 Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 36:255-259.
24. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP 1997 Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int 61:266-271.
25. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New Engl J Med 337:382-387.
26. Skingle SJ, Moore DJ, Crisp AJ 1997 Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy. Int J Clin Pract 51:364-367.
27. Struys A, Snelder AA, Mulder H 1995 Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242.
28. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice M-P, Czachur M, Daifotis AG, Lane N, Correa-Rotter R, Yanover M, Westhovens R, Epstein S, Adachi JD, Poubelle P, Melo-Gomes J, Rodriguez-Portales JA, for the Glucocorticoid-Induced Osteoporosis Intervention Study Group 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299.
29. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ 1998 A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 244:271-292.